The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


Experimental studies have suggested that nicotinamide and its analogs may inhibit the growth of murine tumours. We have now investigated this using a C3H mouse mammary carcinoma implanted into the right rear foot of female CDF1 mice. From days 1 to 30 after implantation mice were intraperitoneally (i.p.) injected with either 100, 200, 500 or 1,000 mg/kg nicotinamide. The tumour volume (+/- 1 S.E.) after 30 days in saline-treated mice had reached 1540 mm3 (+/- 260). No change in tumour growth was seen at that time with daily doses of up to 500 mg/kg nicotinamide, but at 1,000 mg/kg tumour volume was reduced to 904 mm3 (+/- 233). However, this large dose of nicotinamide was also toxic to the mice with some 16% of animals dying during the 30-day treatment period. A similar growth inhibition was seen with daily i.p. injections of 5 mg/kg fumagillin (tumour volume at 30 days = 821 +/- 191 mm3), a known inhibitor of angiogenesis, but whether this mechanism also explains the nicotinamide effect is not clear.
Original languageEnglish
JournalActa Oncologica
Pages (from-to)443-6
Number of pages4
Publication statusPublished - 1995


  • Animals
  • Antineoplastic Agents
  • Cell Division
  • Cyclohexanes
  • Dose-Response Relationship, Drug
  • Fatty Acids, Unsaturated
  • Female
  • Mammary Neoplasms, Experimental
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred Strains
  • Neovascularization, Pathologic
  • Niacinamide
  • Probability
  • Sesquiterpenes


Dive into the research topics of 'The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma'. Together they form a unique fingerprint.

Cite this